*
*Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure
*Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (IDUNN)
A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation
*Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain (MSB-DR003)
https://www.mesoblast.com/product-candidates/clinical-trials
MSB 2022 - The road to commercialisation, page-1431
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.015(1.51%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 97.5¢ | $713.1K | 723.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 95424 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 19085 | 6 |
View Market Depth
| Last trade - 11.55am 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |